A Phase 1 trial of BTRX-335140 in healthy human subjects
Latest Information Update: 08 Apr 2019
At a glance
- Drugs Navacaprant (Primary)
- Indications Anxiety disorders; Mood disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors BlackThorn Therapeutics
- 08 Apr 2019 New trial record
- 01 Apr 2019 Results published in the BlackThorn Therapeutics Media Release
- 01 Apr 2019 According to a BlackThorn Therapeutics media release, data from this trial were presented at the Kappa Therapeutics 2019 Conference